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ABSTRACT 
PURPOSE: In this study, using quantitive VOI analysis, the percentage  99mTc-MAA uptake 
and  SUVmax and mean values of liver metastases obtained prior to SIRT by means of 
Theraspheres were related to treatment response.  
METHODS: Pretreatment FDG PET/CT scans and 99mTc-MAA SPECT/CT scans as well as 
post-treatment FDG PET/CT scans were coregistered and spherical VOI’s drawn around FDG 
positive liver lesions on the pre-treatment scan using CT for contourdelineation. VOIs’ were 
than copied on the 99mTc-MAA SPECT/CT scan and on post-treatment FDG PET/CT scans. 
VOI SUV mean and max values were obtained and the VOI counts derived from the 99mTc-
MAA SPECT/CT images divided by the total 99mTc-MAA counts in the liver lobe or whole 
liver, dependingon the procedure used, yielding the %  of 99mTc-MAA activity injected that 
ended up in the lesions. Based on the VOI % of 99mTc-MAA activity, the estimated 90Y-
Therasphere activity/cc (MBq/cc) was calculated from the effective dose of 90Y-Therasphere 
injected and by dividing with the VOI-volume in cc. Baseline VOI SUVmean and max values 
and estimated MBq/cc values were related to treatment response using a clinical dichotomous 
approach as well as a lesion based approach (% change in SUVmean > 50 %). 
RESULTS: Ninety-one lesions (18 therapeutic sessions in 16 patients) were analyzed; 57 
responded and 34 did not (dichotomous approach). VOI volumes and estimated 90Y-
Therasphere activity (MBq/cc) did not differ between responders and non responders; 24 cc 
(SD: 27) versus 21 cc (sd:21 cc) (p=0.4) and (1.95 MBq/cc (SD: 1.1 MBq/cc) versus 1.90 
MB/cc (SD:2.7 MBq/cc) (p=0.92). Also, activity in MBq/cc was not related to lesion size 
(p=0.32). Contrariwise, SUVmax and mean values proved significantly different between 
responders and non-responders;  23.7 (SD 9.8) versus 9.4 (SD: 3.8 ) for SUVmax (p =0.0001) 
and 13.1 (SD:8.1) versus 4.9(SD:1.4) for SUVmean. ROC curve analysis revealed an AUC 
for SUVmax and mean of respectively 0.87 and 0.81 (p=0.6) for separating responders from 
non-responders. Using the lesional approach and a cut-off of 50 % or more reduction in 
SUVmean for a responding lesion, 40 out of 77 lesions responded and 37 did not. SUVmax 
and mean values also proved significantly different between non-responding and responding 
lesions;  18.6 (SD 10.8) versus 13.5 (SD: 8.4 ) for SUVmax (p =0.02) and 11.4 (SD:3.8) 
versus 6.3(SD:4.5) for SUVmean (p=0.002). ROC curve analysis revealed and AUC for 
SUVmax and SUVmean for separating responding from non-responding lesions of 0.7 and 
0.65 (p= 0.6). 
CONCLUSION: Baseline FDG SUVmax and mean values of non-responders/non-
responding liver metastases to SIRT are significantly higher when compared to 
responders/responding lesions for a comparable estimated 90Y-Therasphere activity/cc. Thus, 
in patients presenting with high baseline SUVmax and mean values, the administration of 
higher activities or alternatively, other potentially more useful treatment options might be 
considered. 
Key words:  SIRT-VOI analysis- treatment response 
  
 INTRODUCTION 
Selective internal radiation therapy (SIRT) or transarterial radioembolization using 90-
Yttrium labelled microspheres involves the intra-arterial injection of commercially available 
90Y-labelled microspheres via the hepatic artery or a side-branch thereof [1-4]. As liver 
metastases are primarily fed via the hepatic artery, following their injection, 90Y-labelled 
microspheres will become entrapped in the tumor vasculature ; 90Y-labelled microspheres are 
small enough to pass deep into the tumor vasculature but too large to pass through the 
capillary bed and reach the venous circulation. Following entrapment in the tumor 
vasculature, 90Y will decay (half-life:  days), emitting  -particles with an average energy of 
0.9367 Mev and a mean tissue penetration of 2.5 mm (maximum penetration = 1 cm).  As 
such SIRT is a form of low-dose rate intra-arterial brachytherapy. As with other forms of 
brachytherapy, the presence of oxygen is a prerequisite for fixing the damaging effects 
induced by the   -radiation via free radical reaction mechanisms in SIRT. Accordingly, when 
confronted with structural hypoxia due to inadequate vascularization, a poor response to SIRT 
may be anticipated.  
In order to confirm access to areas of the liver that need to be treated with 90Y-labelled 
microspheres and in order to isolate liver from other foregut structures, prior to selective 
internal radiation therapy (SIRT) of livermetastases, a 99mTc-MAA scan is performed. As 
99mTc-MAA is assumed to have a similar particle size to that of 90Y-labelled microspheres the 
biodistribution of 99mTc-MAA particles within the liver is also assumed to be similar to that of 
90Y-labelled microspheres and to reflect tumor arterial vascularization relative to normal 
tissue [5,6].  Accordingly, liver lesions with high 99mTc-MAA uptake can be expected to 
receive a high dose of 90Y-labelled microspheres. Inversely, in poorly vascularized liver 
lesions as reflected by a low uptake of 99mTc-MAA a poor response to treatment may be 
anticipated. 
In this study, using quantitive VOI analysis, flow as assessed by 99mTc-MAA imaging and 
metabolism as assessed by FDG PET imaging of liver metastases prior to SIRT was studied 
and findings obtained  related to treatment outcome.  
 
PATIENTS AND METHODS 
In all patients under study, a baseline FDG PET scan was performed within 4 weeks of the 
99mTc-MAA scan as part of a routine work-up on a dedicated BGO PET system with a helical 
CT (Discovery LS; GE Healthcare). Images were acquired 60 minutes following the injection 
of  x MBq FDG, depending on the body mass index of the patient.  
Therasphere treatment was performed as described previously by Salem et al. First an 
angiography was performed for the purpose of coiling collateral gastrointestinal vessels. 
Subsequently, in order to confirm access to areas of the liver that need to be treated with 90Y-
labelled microspheres and in order to isolate liver from other foregut structures as well as to 
assess the degree of lungshunting, at the end of the first angiography a 99mTc-MAA scan was 
performed following the injection of 111 MBq freshly prepared 99mTc-labelled MAA. Both a 
whole body scintigraphy (15 minutes) and a SPECT-CT scan were obtained ( step and shoot 
modus:, matrixsize 128x128) using a dual-headed GE SPECT-CT camera equipped with 
LEHR collimators (Infinia, GE Medical Systems, Milwaukee, WI, USA). Images were 
reconstructed using an ordered subset expectation maximization software programme 
provided by the vendor. In none of the patients included extrahepatic activity occured on the 
99mTc-MAA scan other than in the lungs (estimated dose inferior to 30 Gy, see below): 
percentage lung shunting was < 3% in all patients studied. One to two weeks later, 
Theraspheres were injected during a second angiography targeting a dose of 120 + 20 Gy to 
the target volume whilst not exceeding a dose of 30 Gy to the lungs. The dose was calculated 
as described previously by Salem et al. The volume of the treated liver lobe was considered as 
target volume and measured on CT. Injection of Theraspheres was performed manually using 
the plexiglass-shielded injection system provided by the vendor (Nordion, France). On the 
day of treatment a post-treatment brehmsstrahlung whole body scan and a SPECT-CT of the 
liver was performed to confirm the localization of the 90Y-microspheres in the liver. Patients 
were allowed to leave the hospital the day after the therapeutic injection. Response to 
treatment of liver lesions was assessed between 4-5 weeks following treatment based on 
changes on contrast-enhanced CT findings (available in all patients) and on sequential FDG 
PET/CT imaging (available in 14 treatment sessions) as well as on changes in serum marker 
measurements, when available. In case the patient was deemed a responder, all lesions were 
categorized as responding and vice-versa for non-responders. Aside from this clinical 
dichotomous approach, when a follow-up PET-CT examination was available, a lesion based 
analysis was also performed using a cut-off of < 50% in SUVmax and SUVmean to separate 
non-responding from responding lesions. 
 
IMAGE PROCESSING AND DATA ANALYSIS 
 
Image coregistration 
The baseline FDG PET/CT scan and the 99mTC-MAA SPECT/CT scan were co-registered 
using the baseline FDG PET/CT scan as template using PMOD software (PMOD 
Technologies Ltd.; Zurich, Switzerland). Following image co-registration, images were 
resliced to the voxelsize of the PET images. 
 Lesion delineation and data comparison 
Given the patients in this study were all multi-treated,  CT was not used for  selection of 
relevant lesions given it’s unreliability due to the presence of necrosis or cystic changes. 
Instead, relevant lesions were identified on the FDG PET images. Around  isolated FDG PET 
positive liver lesions  a spherical VOI was drawn that encompassed the lesion as defined on 
the corresponding CT images; minimal diameter of lesions included was 2 cm. From the VOIs 
drawn, the SUVmax and SUVmean values of the lesions were derived. VOIs obtained were 
subsequently copied on the corresponding 99mTc-MAA scan. 99mTc-MAA was injected either 
in the right or left liver lobe or in the common hepatic artery, depending on the planned 
treatment. Separate counts in 99mTc-MAA VOIs and SUV’s in FDG PET VOIs were obtained 
and divided by the total 99mTc-MAA activity in the liver , yielding the % of the dose of 99mTc-
MAA injected that ended up in the lesion as defined by the VOI encompassing it. Thus 
obtained percentages were subsequently used to derive the 90Y-Therasphere activity deposited 
based on the actual dose of 90Y-Therasheres injected, which was subsequently divided by the 
VOI volum in cc, yielding the trapped estimated activity  of 90Y-Theraspheres in MBq/cc. 
While the percentage lung shunting was < 3% in all patients studied, it was deemed to be 0% 
for analysis.  
When available, VOI’s were also copied on the post-therapy FDG PET/CT examination, 
available in 14 sessions, obtained between 4-5 weeks after treatment. For comparison with 
available literature in the field, SUV mean values were also derived from the post-treatment 
FDG PET/CT scan (following image fusion using the baseline examination as reference and 
following copying of the VOIs draw non the baseline ) and the percentage reduction in 
SUVmean calculated [7]. Subsequently, two groups of lesions  were defined, respectively 




Statistical analysis was performed using SPSS version 20.0. Normalcy of data was assessed 
using the Kolmogorov-Smirnov test. Correlation analysis was performed using Pearson-
correlation analysis. An unpaired student t-test was used for assessing differences between 
responding and non-responding lesions in SUV max and mean values as well as in trapped 
90Y-Therasphere activity. ROC curve analysis was also performed. 
 
RESULTS 
Thirteen patients suffering from liver metastases, corresponding to  15 treatment sessions, 
were included in the study (5 men/9 women; age range : 56-79 years). With the exception of 
two patients who underwent a whole liver treatment (single treatment), treatments were 
performed on a lobar base. Nine patients underwent a single, unilobar treatment, in eight 
patients the right liver lobe was treated and in one patient the left lobe was treated.  Two 
patients underwent a separate treatment of their right and left liver lobe. Overall, there were 
15 therapeutic sessions : dose range administered was 0.75 -7.17 GBq (mean : 3.5 GBq).  
Lesion based analysis using a dichotomous clinical approach (responder versus non-
responder): 
Overall, ninety-one lesions were analyzed, of which 57 responded and 34 did not respond to 
treatment (responder versus non-responder). The mean volume of lesions included was 23 cc 
(sd: 26 cc, range 4-155 cc). Mean activity in MBq/cc of 90Y-Theraspheres of all lesions 
analyzed was 1.9 MBq/cc (sd : 1.9, range : 0.2-12.9). Mean SUVmax and SUV mean values 
of all lesions analyzed were respectively 14.2 (sd: 9.6, range : 3.6-38.1) and 7.7 (sd: 6.3, range 
: 2.3-26.7). Activity in MBq/cc was not related to lesion size (p= 0.32, see Figure 1).  
SUVmax and SUV mean of lesions were not significantly correlated with the activity in 
MBq/cc of 90Y-Theraspheres (p = 0.159 and p = 0.141). 
Mean lesional volume proved not significantly different between responding and non-
responding lesions (24cc (sd: 27 cc, range 4-155cc) versus 21 cc (sd : 21 cc, range : 4-113cc), 
( p = 0.4). Activity in MBq/cc of 90Y-Theraspheres proved not significantly different between 
responding and non-responding lesions; 1.95 MBq/cc (sd 1.1 MBq/cc) in non - responding 
lesions versus 1.90 MBq/cc (sd: 2.7 MBq/cc) in responding lesions (p = 0.92).  
Mean SUV max and mean values proved significantly different between non-responding and 
responding lesions; 23.7 (sd: 9.8, range : 4.4-38) for SUV max and  13.1 (sd: 8.1, range : 2.6-
26.7) for SUV mean in non - responding lesions versus  9.4 (sd: 3.8, range : 4-20.1) for SUV 
max and 4.9 (sd: 1.4, range : 2.3-8.6) SUV mean in responding lesions (p = 0.0001). ROC 
curve analysis revealed an AUC for SUV max and SUV mea nfor separating responders from 
non-responders of 0.87 and 0.81 respectively ( p = 0.6). Using a cut-off of 16.3 for SUV max, 
responding lesions could be separated from non-responding lesions with a sensitivity of 85 % 
and a specificity of 95%. See figure 2. Using the average SUV max values of all lesions per 
patient as representative for all liver lesions, ROC curve analysis yielded the same AUC value 
and the cut-off value of 16.3 the same sensitivity and specificity. 
Lesion-based response analysis using a cut-off of < 50% reduction in SUVmean and 
SUVmax (follow-up PET):  
Using a cut-off of 50% or more reduction in mean SUV for a responding lesions, of 77 
evaluable lesions, 40 lesions were shown to respond and 37 not.  On a lesional basis, mean 
lesional volume proved not significantly different between responding and non-responding 
lesions (22cc (sd: 27 cc) versus 23 cc (sd : 23 cc ), ( p = 0.69). Activity in MBq/cc of 90Y-
Theraspheres proved not significantly different between responding and non-responding 
lesions; 1.7 MBq/cc (sd 1.8 MBq/cc) in non - responding lesions versus 2.1 MBq/cc (sd: 2.1 
MBq/cc) in responding lesions (p = 0.47).  
Mean SUV max and mean values proved significantly different between non-responding and 
responding lesions; 18.6 (sd: 10.8, range : 4.6-38.1) for SUV max and  11.4 (sd: 3.8, range : 
3.2-26.7) for SUV mean in non - responding lesions versus  13.5 (sd: 8.4, range : 3.6-33.3) for 
SUV max and 6.3 (sd: 4.5, range : 2.3-21.7) SUV mean in responding lesions (p = 0.02 and p 
=0.002). ROC curve analysis revealed an AUC for SUV max and SUV mean to separate 
responding from non-responding lesions of 0.7 and 0.65 respectively ( p = 0.6).  
 
DISCUSSION 
99mTc-MAA scintigraphy allows assessment of the magnitude of the flux of blood into and of 
the vascular spaces able to accomodate the radioactive micropsheres and their eventual outlets 
that allow particles to escape in both tumourous and non-tumorous livertissue. As the particle 
size of 99mTc-MAA is deemed to be similar to that of Theraspheres, liver lesions with high 
99mTc-MAA uptake may be expected to receive a high dose of 90Y-Theraspheres and thus 
respond better than tumors demonstrating a low uptake. A limited number of studies have 
reported on the predictive value of 99mTc-MAA  imaging for treatment response in SIRT. 
Dhabuwala et al. retrospectively reviewed pretreatment 99mTc-MAA planar scans of 58 
pateints with colorectal hepatic metastases that were treated by SIRT. Tumors were 
qualitatively considered cold, equivocal or hot based on 99mTc-MAA uptake and the ratio of 
uptake in tumor and normal tissue [8]. Data obtained were related to treatment response 
performed using RECIST criteria and changes in serum markers. CT responses and drops in 
CEA level after three months proved similar between patients presenting with “hot” 
metastastases and patients presenting with “equivocal and cold” metastases on 99mTc-MAA 
scans. Flamen et al. mathematically converted liver voxel 99mTc-MAA-SPECT values to the 
absolute 90Y-SIRspheres activity on images obtained in 8 evaluable patients that underwent 
SIRT. Subsequently the absolute 90Y-SIRspheres activity per voxel was than converted to a 
simulated absorbed dose using an S-factor for the liver for 90Y of 18.1 mGy/MBq (residence 
time = 2.67 days) [7]. VOIs encompassing liver metastases, 39 in total, were than defined on a 
pretherapy FDG PET examination using segmentation and copied on the 99mTc-MAA scans 
allowing calculation of the mean simulated absorbed dose value for all voxels within the 
lesion. Additionally, tumor-to-background ratio’s were determined on the 99mTc-MAA images 
for all lesions. Using post-therapy FDG PET imaging for response assessment and a cut-off of 
50 % reduction in total lesion glycolysis of studied lesions, an area under the curve of 0.86 
was found on ROC-analysis for the mean simulated absorbed dose, corresponding linearly to 
the average activity within each VOI of 99mTc-MAA, for separating responding from non-
responding lesions. In the series presented, using a lesion-based approach as well as a patient-
based approach, no difference in activity in MBq/cc of 90Y-Theraspheres and consequently 
also in 99mTc-MAA activity or counts was found between responders and non-responders. 
These findings are, however, not in contradiction with the series by Flamen et al. First,  while 
in the series by Flamen et al. non-responding lesions and responding lesions had similar  
mean SUVmean values, respectively 6.1, in our series, mean SUVmax and SUVmean values 
of non-responding lesions were significantly higher when compared to non responding lesions 
(18.6 and 11.4 versus 13.5 and 6.3; lesional analysis). Second, whereas the average simulated 
activity contained by non-responding lesions was 488+/-392 kBq/ml versus 1329+/1.219 
kBq/ml for responding lesions by Flamen et al.,  in the series presented, non-responding 
lesions (lesional approach) contained an average activity of 2100+/-2100 kBq/ml. This 
activity, which was comparable to the average activity contained by responding lesions in this 
series, is well above the dose received by the responding lesions in the series by Flamen et al. 
The difference in simulated activity contained by lesions between both series is not that 
surprising given the maximum administrable dose for SIRspheres is 3 GBq, regardless of the 
to be treated liver volume, versus 20 GBq for Theraspheres, on the one hand and  the 
currently adopted whole liver approach for SIRspheres versus unilobar approach for 
Theraspheres on the other hand. Hypothetically, the lower activity contained by lesions in the 
series by Flamen et al. might be volume-related; the lesions included for analysis in the series 
by Flamen et al. were significantly larger when compared to this series ( respectively 160+/-
266 cc versus 23+/-6 cc). However, within the range of volumes studied in this study, the 
average activity per volume unit proved unrelated to the lesion volume (see Figure 1).  
Of interest, both the lesional as well as clinical strategy to separate responding lesions from 
non-responding lesions put to evidence a significant difference in SUVmax and SUVmean 
values between both; non responding lesions had a significantly higher FDG uptake when 
compared to responding lesions, while the simulated activity and size-distribution of lesions 
proved identical. From a biological point of view, this may be interpreted as a form of 
advanced adaptation of the tumor to the local environmental conditions, e.g. metabolism 
uncoupling of flow, beyond that secondary to oncogene effects alone resulting in an increase 
in tumor agression and resistance to treatment [9-17]. In this regard, Haug et al. recently 
reported on a significantly shorter survival of patients  suffering from liver metastases of a 
primary breast carcinoma presenting with baseline SUVmax values of liver metastases above 
20, treated by SIRT [18]. Using a cut-off value of 16 for SUVmax, in our series, responding 
lesions as well as responders (averaged values of all lesions per patient) could be separated 
from non-responders with a sensitivity of 85% and a specificity of 95% . Accordingly, in 
patients presenting with  liver metastases with SUVmax values exceeding 16, the injection of 
higher-activities of 90Y-labelled microspheres might be considered, provided the thresholds 
for normal liver and lungs are not exceeded. A similar suggestion was recently also proposed 
by Garin et al. for the treatment of HCC using Theraspheres [19]. Alternatively, other 
potentially useful treatment options may be considered. 
To conclude, in this study, the accumulated percentage activity of 99mTc-MAA and thus of 
dose delivered when performing SIRT using Theraspheres for the treatment of liver 
metastases proved comparable between responding and non-responding lesions. Contrariwise, 
FDG PET SUVmax values of liver metastases on pretreatment FDG PET scans obtained in 
patients scheduled for treatment of livermetastases by means of SIRT proved significantly 
higher in non-responders. Accordingly, above a certain threshold of SUV max , e.g. 16 as 
derived in this series, the administration of higher activities of 90Y-labelled microspheres or 
alternatively, other potentially more useful treatment options might be considered. Additional 
studies in larger patient populations confirming these findings are warranted. 
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Figure 2. Figure 2A illustrates the difference in SUVmax values between non-responders (left boxplot) and 
responders (right box plot). Figure 2B shows the ROC curve analysis for SUVmax and SUVmean to separate 
respodners from non-responders (AUC respectively 0.873 for SUV max and 0.819 for SUVmean). 
 
 
 
